Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Phase I Study of Gemcitabine/Oxaliplatin (GEMOX) and Vandetanib (ZACTIMA; ZD6474) Combination in Patients With Advanced Solid Malignancy (IRUSZACT0070) (UPCI 07-025).

Next Previous
Trial Profile

An Open Label Phase I Study of Gemcitabine/Oxaliplatin (GEMOX) and Vandetanib (ZACTIMA; ZD6474) Combination in Patients With Advanced Solid Malignancy (IRUSZACT0070) (UPCI 07-025).

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Feb 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vandetanib (Primary) ; Gemcitabine; Oxaliplatin
  • Indications Solid tumours
  • Focus Adverse reactions

Most Recent Events

  • 21 Jan 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
  • 17 Jan 2013 Planned end date changed from 1 Oct 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
  • 28 Apr 2011 Planned end date changed from 1 Oct 2010 to 1 Oct 2012 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top